Showing results (501-510 of 586) with videos related to

Sort By:
Pageof 59
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2010
Increased incidence of visceral metastases in scottish patients with BRCA1/2-defective ovarian cancer: an extension of the ovarian BRCAness phenotypeCharlie Gourley, Caroline O Michie, Patricia Roxburgh, et al.
Investigational New Drugs|September 25, 2021
Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib studyKyaw Z Thein, Daniel D Karp, Apostolia Tsimberidou, et al.
Nature Medicine|October 19, 2025
YAP/TEAD inhibitor VT3989 in solid tumors: a phase 1/2 trialTimothy A Yap, David J Kwiatkowski, Ibiayi Dagogo-Jack, et al.
Journal of the National Cancer Institute|May 6, 2024
Ataxia telangiectasia and Rad3-related (ATR) inhibitor camonsertib dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study)Elisa Fontana, Ezra Rosen, Elizabeth K Lee, et al.
Journal of Immunotherapy and Precision Oncology|February 8, 2024
Limited Independent Follow-Up with Germline Testing of Variants Detected in BRCA1 and BRCA2 by Tumor-Only SequencingCarol J Nowlen, Molly Daniels, Burak Uzunparmak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2010
Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free intervalPeter C Fong, Timothy A Yap, David S Boss, et al.
British Journal of Cancer|July 15, 2010
The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label studyL R Molife, P C Fong, L Paccagnella, et al.
Plos One|November 13, 2012
Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancersGeraldine Perkins, Timothy A Yap, Lorna Pope, et al.
NPJ Precision Oncology|July 15, 2023
Actionability classification of variants of unknown significance correlates with functional effectAmber Johnson, Patrick Kwok-Shing Ng, Michael Kahle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 5, 2011
Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignanciesDavid Olmos, Douglas Barker, Rohini Sharma, et al.
Pageof 59